Glucose Monitoring for Gestational Diabetes

No longer recruiting at 1 trial location

Overseen By Thomas Owens, MD

Age: 18+

Sex: Female

Trial Phase: Academic

Sponsor: Icahn School of Medicine at Mount Sinai

Disqualifiers: Under 18, Multiple gestation, C-section

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines how different methods of monitoring blood sugar during labor affect newborns' blood sugar levels. Women with gestational diabetes (a type of diabetes that occurs during pregnancy) will be divided into two groups: one with more frequent blood sugar checks and one with fewer. The goal is to determine if the frequency of these checks impacts the baby's health immediately after birth. Pregnant individuals with gestational diabetes who are in labor with one baby may qualify for this trial. As an unphased study, this trial provides a unique opportunity to contribute to understanding the best care practices for newborns.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this glucose monitoring protocol is safe for gestational diabetes?

Research has shown that checking blood sugar during pregnancy is generally safe. Studies, including those on continuous glucose monitoring with pregnant women who have diabetes, indicate that it is usually well-tolerated.

Finger stick tests are a common method for checking blood sugar. This practice is important for managing diabetes and typically does not cause serious side effects. Most people find this method reliable and safe. Regular blood sugar checks help maintain stable levels, which is crucial for the health of both mother and baby.

Overall, glucose monitoring has a strong safety record. Studies have not reported any major safety concerns with this method. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the glucose monitoring trial for gestational diabetes because it could refine how often blood sugar levels are checked during labor. Traditionally, glucose monitoring involves a standard schedule of checks, but this trial compares less frequent versus more frequent testing. The goal is to find out if altering the frequency can improve outcomes for both the mother and baby by ensuring better glucose control during labor. If successful, this could lead to more personalized and efficient monitoring strategies, potentially enhancing maternal and neonatal health without adding unnecessary stress or interventions.

What evidence suggests that this glucose monitoring protocol is effective for gestational diabetes?

This trial will compare different frequencies of glucose monitoring for managing gestational diabetes. Research has shown that frequent blood sugar checks can improve management of gestational diabetes. Studies have found that continuous glucose monitoring systems, which track blood sugar levels constantly, can lead to healthier pregnancies for those with diabetes. Better blood sugar control is linked to fewer complications for both mother and baby. While some studies suggest this monitoring might not directly improve newborn outcomes, it provides detailed information on blood sugar levels, crucial for managing gestational diabetes. Overall, although the exact benefits for babies are still under study, maintaining stable blood sugar levels is generally beneficial. ^{6 7 8 9 10}

Who Is on the Research Team?

Thomas Owens, MD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Are You a Good Fit for This Trial?

This trial is for pregnant individuals with Gestational Diabetes Mellitus (GDM). It's designed to see if the frequency of checking blood sugar levels during labor affects their newborns' risk of low blood sugar. Participants will be randomly assigned to either 'frequent' or 'infrequent' glucose monitoring groups.

Inclusion Criteria

Patient with singleton gestation presenting in labor or for induction

I am of childbearing age and have been diagnosed with gestational diabetes.

Exclusion Criteria

Multiple gestation pregnancy

Patients undergoing scheduled c-section

I am under 18 years old.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intrapartum Glucose Monitoring

Participants with Gestational Diabetes Mellitus (GDM) undergo either frequent or infrequent glucose monitoring during labor

Duration of labor

Continuous monitoring during labor

Follow-up

Participants are monitored for neonatal hypoglycemia and other outcomes

6 months

What Are the Treatments Tested in This Trial?

Interventions

• Frequency of Glucose Monitoring

Trial Overview

The study tests two different approaches to monitor blood sugar in laboring mothers with GDM: one group will have their glucose checked frequently, while the other less so. The main goal is to observe how these methods impact the baby's blood sugar level at birth.

How Is the Trial Designed?

Group I: Infrequent testing Experimental Treatment 1 Intervention

Finger sticks every 4 hours in latent labor (less than 5cm cervical dilation) and every 2 hours in active labor (6cm and greater)

Group II: Frequent testing Placebo Group 1 Intervention

Finger sticks every 2 hours in latent labor (less than 5cm cervical dilation) and every 1 hours in active labor (6cm and greater)

Frequency of Glucose Monitoring is already approved in European Union, United States for the following indications:

Approved in European Union as Glucose Monitoring for:

• Gestational Diabetes Mellitus (GDM)
• Type 1 Diabetes
• Type 2 Diabetes

Approved in United States as Glucose Monitoring for:

• Gestational Diabetes Mellitus (GDM)
• Type 1 Diabetes
• Type 2 Diabetes

Who Is Running the Clinical Trial?

Icahn School of Medicine at Mount Sinai

Lead Sponsor

Trials

933

Recruited

579,000+

Published Research Related to This Trial

A team approach to diabetes management during pregnancy is crucial for optimizing outcomes for both the mother and baby, requiring intensive insulin therapy and careful glucose monitoring before and during pregnancy.

Universal screening for gestational diabetes at 24 to 28 weeks is essential, and initial dietary management may be supplemented with insulin therapy if glucose levels remain elevated, highlighting the importance of ongoing monitoring and long-term follow-up for women with gestational diabetes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Management of diabetes in pregnancy. Pasui, K., McFarland, KF.[2005]

In a study involving 65 women with various types of diabetes during pregnancy, it was found that the peak postprandial blood glucose levels occur approximately 90 minutes after meals, regardless of the type of diabetes or glycemic control.

About 50% of the participants did not return to their pre-meal glucose levels within 3 hours, highlighting the need for careful monitoring and management of blood glucose in diabetic pregnancies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The postprandial glucose profile in the diabetic pregnancy. Ben-Haroush, A., Yogev, Y., Chen, R., et al.[2004]

In a study of 1302 pregnant women with gestational diabetes mellitus (GDM), continuous glucose monitoring (CGM) metrics were found to be associated with an increased risk of adverse pregnancy outcomes, such as preterm birth and NICU admission, indicating the importance of glucose control during pregnancy.

Specific CGM-derived thresholds, such as a time above range (TAR) of 2.5% and a daily mean blood glucose (MBG) of 4.8 mmol/L, could help identify women at higher risk for complications, suggesting that these metrics may be useful targets for interventions to improve pregnancy outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Continuous glucose monitoring-derived glycemic metrics and adverse pregnancy outcomes among women with gestational diabetes: a prospective cohort study. Liang, X., Fu, Y., Lu, S., et al.[2023]

Self-monitoring of blood glucose in women with mild gestational diabetes effectively reduces fetal overgrowth and gestational weight gain, highlighting its importance in managing this condition.

Continuous glucose monitoring systems may benefit pregnant women with insulin-treated diabetes, particularly those with challenging blood sugar control or nocturnal hypoglycemia, but further research through larger randomized trials is needed to confirm their efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Glucose monitoring during pregnancy. Hawkins, JS.[2022]

Tight glycemic control during pregnancy is crucial, as it significantly reduces risks for both the mother and fetus, with recommended blood glucose targets between 70 to 120 mg/dL.

Effective management of pregestational and gestational diabetes relies on regular blood glucose monitoring, which should be integrated into treatment plans to ensure timely adjustments in therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Measuring and managing hyperglycemia in pregnancy: from glycosuria to continuous blood glucose monitoring. Mazze, RS.[2022]

In a study of 117 pregnant patients with type 1 or 2 diabetes, continuous glucose monitoring (CGM) metrics were linked to neonatal outcomes, showing that higher time in range (TIR) significantly reduces the odds of neonatal morbidity by 28% for every 5 percentage-point increase in TIR.

The optimal TIR for improving neonatal outcomes was found to be between 66-71%, supporting the American Diabetes Association's recommendation of aiming for at least 70% TIR during pregnancy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Association of Continuous Glucose Monitoring Metrics With Pregnancy Outcomes in Patients With Preexisting Diabetes. Sanusi, AA., Xue, Y., McIlwraith, C., et al.[2023]

The Continuous Glucose Monitoring System (CGMS) demonstrated a high accuracy in reflecting glucose levels in pregnant women with type 1 diabetes, with a correlation coefficient of 0.94 based on 239 analyzed blood glucose values.

An impressive 93.8% of the non-calibration glucose readings fell within the clinically acceptable range according to the Clarke error grid analysis, indicating that CGMS can be a reliable tool for monitoring glucose in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The Continuous Glucose Monitoring System during pregnancy of women with type 1 diabetes mellitus: accuracy assessment. Kerssen, A., de Valk, HW., Visser, GH.[2006]

In a study of 115 pregnant women with diabetes, higher mean glucose levels in the second trimester were linked to an increased risk of having large for gestational age (LGA) babies, particularly in those with type 1 diabetes.

The area under the curve for glucose levels above the target range was significantly associated with LGA in type 2 diabetes and insulin-treated gestational diabetes, but no CGM metrics were found to correlate with other adverse outcomes like neonatal hypoglycemia or preterm birth.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Continuous glucose monitoring metrics and pregnancy outcomes in insulin-treated diabetes: A post-hoc analysis of the GlucoMOMS trial. Rademaker, D., van der Wel, AWT., van Eekelen, R., et al.[2023]

In a study of 40 patients with gestational diabetes, real-time continuous glucose monitoring did not significantly improve mean glucose levels compared to blinded continuous glucose monitoring after 4 weeks of use.

There were no notable differences in glycemic control or maternal and neonatal outcomes between the two monitoring methods, suggesting that real-time feedback may not provide additional benefits over intermittent self-monitoring.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-Time Continuous Glucose Monitoring in Gestational Diabetes: A Randomized Controlled Trial. Lane, AS., Mlynarczyk, MA., de Veciana, M., et al.[2022]

Continuous glucose monitoring (CGM) is becoming a recommended method for managing blood sugar levels in pregnant women with diabetes, as it is less invasive than traditional blood glucose measurements.

Optimal glycemic control during pregnancy is crucial for improving both maternal and neonatal outcomes, highlighting the importance of effective monitoring strategies like CGM.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Continuous Glucose Monitoring in Pregnancy. Horgan, R., Hage Diab, Y., Fishel Bartal, M., et al.[2023]

Citations

1.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/28594772/

Gestational Diabetes Mellitus and Frequency of Blood ...

Objective: To assess whether testing blood glucose four times daily compared with four times every other day would lead to similar birth weights among patients ...

2.

diabetesjournals.org

diabetesjournals.org/care/article/48/9/1581/163057/Real-Time-Continuous-Glucose-Monitoring-in

Real-Time Continuous Glucose Monitoring in Pregnancies ...

The control group used CBG monitoring four times per day underwent blinded CGM approximately every 20 days throughout the study period. The ...

3.

sciencedirect.com

sciencedirect.com/science/article/pii/S0002937825002170

Evidence for improved glucose metrics and perinatal ...

Within diabetes in pregnancy, continuous glucose monitoring use (vs self-monitoring of blood glucose) showed similar but stronger benefits in both type 1 ...

4.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12335106/

Continuous glucose monitoring system in diabetes ...

A retrospective cohort study evaluating 65 pregnant women with T2D and GDM found that both isCGM and rtCGM improved glycemic control. However, ...

5.

thelancet.com

thelancet.com/journals/landia/article/PIIS2213-8587(25)00063-4/fulltext

Continuous glucose monitoring in the management of ...

Our results show that the outcome in individuals with gestational diabetes is not improved by the use of rtCGM. However, individuals expressed a ...

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06373432

NCT06373432 | Frequency of Glucose Monitoring in Labor

Study Overview. Brief Summary. The aim of this study is to assess rates of neonatal hypoglycemia with differing intrapartum glucose protocols.

7.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC8755615/

Reexamining intrapartum glucose control in patients with ...

Tight intrapartum glycemic monitoring and control in women with diabetes is postulated to decrease the risk of fetal acidemia, neonatal ...

8.

withpower.com

withpower.com/trial/phase-hypoglycemia-3-2024-ac843

Glucose Monitoring for Gestational Diabetes

Glucose monitoring, including continuous glucose monitoring, has been studied in pregnant women with diabetes and is generally considered safe, though more ...

9.

mdpi.com

mdpi.com/2075-1729/15/9/1369

Exploring Continuous Glucose Monitoring in Gestational ...

(4) Conclusions: the CGMS offers a more detailed assessment of both maternal and fetal exposure to high glucose levels, which could lead to earlier detection of ...

10.

diabetesresearchclinicalpractice.com

diabetesresearchclinicalpractice.com/article/S0168-8227(24)00095-0/fulltext

Accuracy of intermittently scanned continuous glucose ...

The accuracy of isCGM during caesarean delivery was good, particularly for glucose values between 70 and 110 mg/dL, when CG confirmation could be safely ...